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Lipidomics need more standarization  
Lipidomics Standards Initiative Consortium* 
  
Summary 
Modern mass spectrometric technologies provide quantitative readouts for a wide variety of 
lipid specimens. However, many studies do not report absolute lipid concentrations and differ 
vastly in methodologies, workflows, and data presentation. Therefore, we appeal to 
researchers to engage with the Lipidomics Standards Initiative to develop common standards 
for minimum acceptable data quality and reporting for lipidomics data to take lipidomics 
research to the next level.  
Current state of lipidomics 
Lipidomics has evolved rapidly over the past decade as it offers new opportunities for studying 
the role of lipids in cellular biology as well as in health and disease 1. Lipidomes of eukaryotic 
cells comprise hundreds of individual lipid species that structurally and chemically regulate 
cell membranes dynamics, store energy, and/or serve as precursors of bioactive metabolites 
2. Membranes of cells and organelles have unique lipid compositions which are intimately 
linked to their biological functions. The biophysical properties of membranes are also affected 
by seemingly minor structural differences between individual lipid species, such as the 
number, position and geometry of double bonds in acyl chains. These characteristics drive 
membrane budding/fission events and may regulate protein function 3. Lipid species in 
membranes act not as single molecules but as a collective which needs to be analyzed 
quantitatively and comprehensively to understand their biological function. Examples of 
bioactive lipid species include typical membrane lipids, such as ceramide (Cer) d18:1/16:0 as 
a selective natural ligand of p53 4, or fatty acid-derived pro-inflammatory (i.e. prostaglandins, 
leukotrienes) and anti-inflammatory (i.e. resolvins, protectins, maresins) mediators 5. The 
power of lipidomics is further demonstrated by the identification of ceramide species as risk 
markers for cardiovascular disease from independent large-scale lipidomics studies 6,7. These 
and other intriguing results have spurred interest in adopting lipidomics capabilities across 
research communities. 
A major challenge in the field of lipidomics, however, is the large disparity in methodologies 
and technologies, resulting in discrepancies in published data and broader issues of 
irreproducibility 8. Common problems include improper annotation of lipid species (despite the 
publication of an accurate shorthand annotation for lipid species in 2013 9), misidentifications 
and overreporting, likely caused by incorrect mapping of mass spectral features to potential 
lipid molecules due to software errors combined with the a lack of manual data inspection or 
curation. Similarly, the reporting of data in arbitrary units (usually ion counts of peak intensity 
or area) is commonly used even though only quantification of molecule numbers (i.e., mol) 
allows calculating the fractions for lipid classes and species and being the only adequate 
solution for detailed interpretation and comparison of data sets. Detailed structural analysis of 
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lipids, such as the identification of double bond positions in acyl chains, are needed for a 
functional decoding of individual lipids to advance lipid biology. 
 
Why we need standards for lipidomics 
 An inter-laboratory comparison involving the quantification of lipids in human plasma 
demonstrated that the diversity of lipid analysis strategies is reflected in the variation of 
concentrations of the measured lipid species 10. We believe that a community-wide, open 
discussion of the methods used and how lipidomics data are presented is needed to achieve 
accurate quantification and reproducibility of results. This effort should identify issues, as 
mentioned above, in lipidomic workflows and develop guidelines for the entire lipidomic 
process, from preanalytics, lipid extractions, mass spectrometric analysis, data analysis and 
reporting. One such initiative is already ongoing specifically for the lipidomic analysis of human 
plasma 11.  
Such guidelines should be adapted, where appropriate, from existing “omics” guidelines 12,13. 
However, lipidomics differs in certain aspects from other omics strategies so that it requires 
its own set of standards 14 (Figure 1). One advantage, compared to other “omics” fields, is 
that the fragmentation pathways for most of the existing lipid classes are known. This allows 
us to define rules for the identification of lipid species rather than relying on spectral similarities 
between lipids. Thus, lipid identification can be improved by annotating lipids correctly in 
accordance with the obtained mass spectrometry data 9 and through the use of internal 
standards, which allow for accurate quantification 14. 
Lipidomic analyses are particularly challenging due to the richness in isomeric species, mainly 
resulting from variations in acyl chain length and the position of double bonds. For example, 
lipids that differ merely in the number of double bonds generate substantial isotopic overlap 
particularly resulting from 13C-atoms. Thus, the M+2-isotopic peak for a typical phospholipid is 
above 10% related to its monoisotopic peak and overlaps with a species containing one double 
bond less. Lipids are also prone to artifacts as a result of in-source fragmentation, including 
during sampling by autoxidation and action of lipases 8. Although semi-quantitative 
approaches may be applicable for biomarker discovery or provide valid data on relative 
changes of lipid species, we think lipidomic methods need to allow for quantitative analysis in 
order to study the interplay of lipids in biological membranes. However, the quantification of a 
large number of lipid species requires tailored approaches.  
 
 
Figure 1. Analytical challenges in lipidomics workflows. Bold terms are of particular 
importance for lipidomic workflows. 
The Lipidomics Standards Initiative 
The Lipidomics Standards Initiative (LSI; https://lipidomics-standards-initiative.org/) was 
launched in spring 2018 to address these challenges. Since then, the LSI has participated in 
several workshops and conferences to propose the introduction of guidelines and standards 
for lipidomics, which we hope will improve the overall understanding of analytical chemistry 
(mass spectrometric analysis) and lipid biology, which should be particularly useful to 
researchers that are new to the lipidomics field. We believe it is time to increase the awareness 
of the LSI, not only within the lipidomics community, but also among metabolomics 
researchers working in related disciplines who produce lipid data sets.  
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Importantly, our commitment is to align the LSI with existing initiatives to develop guidelines 
for lipidomics. We have established a collaboration with LIPID MAPS 
(https://www.lipidmaps.org/), are currently discussing an adaptation of mzTab 15 to report 
lipidomic data, and have started an active dialogue with other initiatives and communities. For 
instance, the LSI promotes development of lipo-centric hierarchical databases like SwissLipids 
(http://www.swisslipids.org/) and LipidHome (https://www.ebi.ac.uk/metabolights/lipidhome/) 
as well as search tools like “Bulk” structure searches of LIPID MAPS 
(https://www.lipidmaps.org/resources/tools/bulk_structure_searches_overview.php). 
 
The LSI homepage contains the first drafts of guidelines which cover all steps of the most 
common lipidomic workflows (https://lipidomics-standards-initiative.org/guidelines) in an effort 
to stimulate discussion and to promote their development. The LSI is outward facing in that 
anyone can directly communicate with the LSI community through discussion boards on the 
homepage, an interaction we highly encourage. The guidelines found on the LSI website 
include the various analytical steps in a lipidomics workflow, guiding how to (i) collect and store 
samples, (ii) extract lipids, (iii) execute the MS analysis, (iv) perform data processing, including 
lipid identification, deconvolution, annotation, quantification, and evaluation of quality control, 
and (v) how to report the data. The guidelines also cover the validation of analytical methods 
and the use of quality controls. Lack of, or failure, in following a set of rules or guidelines, 
increases the likelihood of errors occurring during all stages of the lipidomics workflow, leading 
to data irreproducibility and incorrect reporting or interpretation. Therefore, LSI aims to provide 
a checklist to guide users in how to achieve a minimum acceptable level of data quality and to 
inform editors, as well as reviewers, who evaluate manuscripts containing lipidomic data.  
 
Conclusions 
Guidelines about standards for lipidomics are required to unlock the full potential of lipidomics. 
Such guidelines will be key for lipidomics to meet regulatory requirements in order for 
lipidomics to be used in clinical research and diagnostics. In order to transit to clinical 
diagnostics, validation of lipidomics methods need to comply to FDA and EMA requirements. 
In basic research, lipidomics standards will enhance the comparability of data and, combined 
with resources of lipid species profiles for specific biological materials including human and 
murine body fluids and tissues, these standardization efforts will enhance our understanding 
of the functional roles of specific lipid species.  
Taken together, we report the first steps towards urgently needed lipidomics standardization. 
Posting a first draft of guidelines represents a strong request to the community to engage with 
the LSI in order to facilitate implementation and continuous development of standards. We 
encourage researchers to use our discussion board or to connect directly to one of the LSI 
members. Embarking on lipidomics standardization now, represents the unique chance to 
introduce guidelines in an emerging community. Missing this opportunity will waste resources 
and hamper the broad adoption of standards due to a rapidly growing number of lipidomics 
users, applications and methods. 
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